EXEL:NASDAQExelixis, Inc. Analysis
Data as of 2026-08-25 - not real-time
$56.12
Latest Price
5/10Risk
Risk Level: Medium
Executive Summary
At $56.12, Exelixis, Inc. shows no decisive moving-average alignment, leaving the trend neutral. With RSI at 58.4 the momentum picture is neutral, alongside a bullish MACD signal. The recent range runs from support at $49.97 up to resistance at $56.95.
The shares look fair, trading on 17.6 times earnings below a sector average of 31.2. The average analyst target implies 5.6% below today's level. Revenue is growing at 10.6% on a 35.3% profit margin.
Risk scores 5 out of 10, which is moderate for this asset class. With 30-day volatility of 40.3%, a beta of 0.61 and a maximum drawdown of 16.5%, position sizing matters here. The wider market backdrop reads extreme greed at 93 on the fear-greed composite.
Across every horizon the signals point the same way: buy, at a conviction of 4 out of 10.
The shares look fair, trading on 17.6 times earnings below a sector average of 31.2. The average analyst target implies 5.6% below today's level. Revenue is growing at 10.6% on a 35.3% profit margin.
Risk scores 5 out of 10, which is moderate for this asset class. With 30-day volatility of 40.3%, a beta of 0.61 and a maximum drawdown of 16.5%, position sizing matters here. The wider market backdrop reads extreme greed at 93 on the fear-greed composite.
Across every horizon the signals point the same way: buy, at a conviction of 4 out of 10.
Top Market Events
In early August 2026, Exelixis reported second-quarter results showing revenue of US$628.Exelixis Inc EXEL reports robust Q2 2026 results with $629M in revenues, while navigating slower NET adoption and...While the top- and bottom-line numbers for Exelixis EXEL give a sense of how the business performed in the quarter...
Market Outlook
Short Term
< 1 yearPositive
Model confidence: 4/10
Key Factors
- Trading above the 200-day average of 47.06
- MACD momentum is positive
- 30-day volatility of 40.3%
Medium Term
1–3 yearsPositive
Model confidence: 4/10
Key Factors
- P/E of 17.6 versus sector average of 31.2
- Trading above the 200-day average of 47.06
- Analyst targets imply -5.6% versus the current price
Long Term
> 3 yearsPositive
Model confidence: 4/10
Key Factors
- P/E of 17.6 versus sector average of 31.2
- Analyst targets imply -5.6% versus the current price
- Profit margin of 35.3% is healthy
Key Metrics & Analysis
Financial Health
Revenue Growth10.60%
Profit Margin35.33%
P/E Ratio17.6
ROE44.39%
ROA23.97%
Debt/Equity9.00
P/B Ratio7.6
Op. Cash Flow$1.2B
Free Cash Flow$739.7M
Industry P/E31.2
Technical Analysis
TrendNeutral
RSI58.4
Support$49.97
Resistance$56.95
MA 20$53.66
MA 50$54.32
MA 200$47.06
MACDBullish
VolumeDecreasing
Fear & Greed Index93.34
Valuation
Fair Value$61.95
Target Price$53.00
Upside/Downside-5.56%
GradeFair
TypeGrowth
Risk Assessment
Beta0.61
Volatility40.29%
Sector RiskMedium
Reg. RiskHigh
Geo RiskLow
Currency RiskLow
Liquidity RiskLow
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.